William H. Chappell

7.0k total citations · 1 hit paper
41 papers, 4.0k citations indexed

About

William H. Chappell is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, William H. Chappell has authored 41 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 19 papers in Oncology and 8 papers in Pathology and Forensic Medicine. Recurrent topics in William H. Chappell's work include PI3K/AKT/mTOR signaling in cancer (19 papers), Cancer-related Molecular Pathways (11 papers) and Melanoma and MAPK Pathways (10 papers). William H. Chappell is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (19 papers), Cancer-related Molecular Pathways (11 papers) and Melanoma and MAPK Pathways (10 papers). William H. Chappell collaborates with scholars based in United States, Italy and Germany. William H. Chappell's co-authors include James A. McCubrey, Linda S. Steelman, Stephen L. Abrams, Massimo Libra, Alberto M. Martelli, Franca Stivala, Jörg Bäsecke, Brian D. Lehmann, David M. Terrian and Richard A. Franklin and has published in prestigious journals such as Blood, Oncogene and Journal of Virology.

In The Last Decade

William H. Chappell

41 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

2006 1.9k citations James A. McCubrey, Linda S. Steelman et al. profile →

Peers

William H. Chappell

ONCOL

PFM

PRM

Patrick M. Navolanic United States

Pixu Liu China

Jörg Bäsecke Germany

William L. Blalock Italy

Jingxuan Pan China

Fumin Chang United States

Christopher L. Morton United States

Franca Stivala Italy

Borhane Annabi Canada

Benjamin D. Hopkins United States

Patrick M. Navolanic United States

William H. Chappell

2.3k ×0.8

1.0k ×0.8

ONCOL

562 ×0.8

403 ×0.9

PFM

371 ×0.9

PRM

Citations per year, relative to William H. Chappell William H. Chappell (= 1×) peers Patrick M. Navolanic

Countries citing papers authored by William H. Chappell

Since Specialization

Citations

This map shows the geographic impact of William H. Chappell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William H. Chappell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William H. Chappell more than expected).

Fields of papers citing papers by William H. Chappell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William H. Chappell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William H. Chappell. The network helps show where William H. Chappell may publish in the future.

Co-authorship network of co-authors of William H. Chappell

This figure shows the co-authorship network connecting the top 25 collaborators of William H. Chappell. A scholar is included among the top collaborators of William H. Chappell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William H. Chappell. William H. Chappell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Steelman, Linda S., William H. Chappell, Shaw M. Akula, et al.. (2020). Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling. Advances in Biological Regulation. 78. 100758–100758. 28 indexed citations

Chappell, William H., Saverio Candido, Stephen L. Abrams, et al.. (2018). Roles of p53, NF-κB and the androgen receptor in controlling NGAL expression in prostate cancer cell lines. Advances in Biological Regulation. 69. 43–62. 19 indexed citations

Chappell, William H., Stephen L. Abrams, Kvin Lertpiriyapong, et al.. (2015). Novel roles of androgen receptor, epidermal growth factor receptor, TP53, regulatory RNAs, NF-kappa-B, chromosomal translocations, neutrophil associated gelatinase, and matrix metalloproteinase-9 in prostate cancer and prostate cancer stem cells. Advances in Biological Regulation. 60. 64–87. 30 indexed citations

Sokolosky, Melissa L., William H. Chappell, Kristin M. Stadelman, et al.. (2014). Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells. Cell Cycle. 13(5). 820–833. 43 indexed citations

Ciuffreda, Ludovica, Ursula Cesta Incani, Linda S. Steelman, et al.. (2014). Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLC. Current Pharmaceutical Design. 20(24). 3944–3957. 52 indexed citations

Chappell, William H., Stephen L. Abrams, Kristin M. Stadelman, et al.. (2012). Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment. Advances in Biological Regulation. 53(1). 146–155. 12 indexed citations

Chappell, William H., Stephen L. Abrams, Richard A. Franklin, et al.. (2012). Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. Cell Cycle. 11(23). 4447–4461. 21 indexed citations

Steelman, Linda S., Patrick M. Navolanic, William H. Chappell, et al.. (2011). Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle. 10(17). 3003–3015. 70 indexed citations

Steelman, Linda S., Richard A. Franklin, Stephen L. Abrams, et al.. (2011). Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia. 25(7). 1080–1094. 203 indexed citations

10.

Abrams, Stephen L., Linda S. Steelman, John G. Shelton, et al.. (2010). The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle. 9(9). 1781–1791. 103 indexed citations

11.

Abrams, Stephen L., Linda S. Steelman, John G. Shelton, et al.. (2010). Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy. Cell Cycle. 9(9). 1839–1846. 21 indexed citations

12.

McCubrey, James A., William H. Chappell, Stephen L. Abrams, et al.. (2010). Targeting the cancer initiating cell: The Achilles’ heel of cancer. Advances in Enzyme Regulation. 51(1). 152–162. 9 indexed citations

13.

McCubrey, James A., Linda S. Steelman, Steven L. Abrams, et al.. (2009). Emerging Raf inhibitors. Expert Opinion on Emerging Drugs. 14(4). 633–648. 26 indexed citations

14.

Lehmann, Brian D., et al.. (2008). Distinct roles for p107 and p130 in Rb-independent cellular senescence. Cell Cycle. 7(9). 1262–1268. 15 indexed citations

15.

Lee, John Tayu, Brian D. Lehmann, David M. Terrian, et al.. (2008). Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle. 7(12). 1745–1762. 83 indexed citations

16.

Steelman, Linda S., Kristin M. Stadelman, William H. Chappell, et al.. (2008). Akt as a therapeutic target in cancer. Expert Opinion on Therapeutic Targets. 12(9). 1139–1165. 120 indexed citations

17.

Lee, John Tayu, Linda S. Steelman, William H. Chappell, & James A. McCubrey. (2008). Akt inactivates ERK causing decreased response to chemotherapeutic drugs in advanced CaP cells. Cell Cycle. 7(5). 631–636. 29 indexed citations

18.

McCubrey, James A., Linda S. Steelman, Richard A. Franklin, et al.. (2007). Targeting the RAF/MEK/ERK, PI3K/AKT and P53 pathways in hematopoietic drug resistance. Advances in Enzyme Regulation. 47(1). 64–103. 67 indexed citations

19.

Bertrand, F. E., Linda S. Steelman, William H. Chappell, et al.. (2006). Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells. Leukemia. 20(7). 1254–1260. 68 indexed citations

20.

Chappell, William H., et al.. (2005). Increased Protein Expression of the PTEN Tumor Suppressor in the Presence of Constitutively Active Notch-1. Cell Cycle. 4(10). 1389–1395. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact